Maron Ruth, Slavin Anthony J, Hoffmann Ethan, Komagata Yoshinori, Weiner Howard L
Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA 02115, USA.
Int Immunol. 2002 Feb;14(2):131-8. doi: 10.1093/intimm/14.2.131.
Oral tolerance to myelin basic protein (MBP) is an effective antigen-specific method to suppress experimental allergic encephalomyelitis (EAE). Glatiramer acetate [copolymer 1 (Cop1)] is a synthetic copolymer designed to mimic MBP which suppresses EAE, is used parenterally to treat multiple sclerosis (MS) and is being tested orally for efficacy in MS. We investigated the immunologic properties of Cop1 to determine the degree to which its effects were antigen specific using MBP TCR transgenic mice. Immunization of MBP TCR transgenic mice fed Cop1, MBP or MBP Ac1-11 resulted in decreased proliferation, and IL-2, IL-6 and IFN-gamma production, and increased secretion of IL-10 and transforming growth factor (TGF)-beta in Cop1-fed animals. IFN-gamma was decreased, and IL-10 and TGF-beta were increased in non-immunized mice fed Cop1 and stimulated in vitro with MBP. No such effects were observed in ovalbumin TCR transgenic mice. To determine if the effects of Cop1 were specific to MBP TCR-bearing cells, MBP TCR transgenic Rag2(-/-) mice were immunized and re-stimulated in vitro with Cop1. We found a marked increase in IL-4 and similar increases in IL-4 after feeding Cop1. In disease models, feeding Cop1 suppressed EAE in MBP TCR transgenic mice, (PL/J x SJL)F(1) mice, and in myelin oligodendrocyte glycoprotein-induced EAE in NOD mice. Oral Cop1 had no effect on collagen-induced arthritis. These results demonstrate that Cop1 is active orally in an antigen-specific fashion, and may function as an altered peptide ligand for MBP-specific TCR-bearing cells by decreasing pro-inflammatory cytokines (IFN-gamma) and increasing anti-inflammatory cytokines (IL-4, IL-10 and TGF-beta).
对髓鞘碱性蛋白(MBP)的口服耐受是一种抑制实验性自身免疫性脑脊髓炎(EAE)的有效抗原特异性方法。醋酸格拉替雷[共聚物1(Cop1)]是一种合成共聚物,设计用于模拟抑制EAE的MBP,它通过肠胃外给药治疗多发性硬化症(MS),目前正在进行口服治疗MS的疗效测试。我们研究了Cop1的免疫学特性,以确定其使用MBP TCR转基因小鼠时抗原特异性作用的程度。给喂食Cop1、MBP或MBP Ac1-11的MBP TCR转基因小鼠免疫后,Cop1喂养组动物的增殖、IL-2、IL-6和IFN-γ产生减少,IL-10和转化生长因子(TGF)-β分泌增加。喂食Cop1并在体外以MBP刺激的未免疫小鼠中,IFN-γ减少,IL-10和TGF-β增加。在卵清蛋白TCR转基因小鼠中未观察到此类作用。为了确定Cop1的作用是否对携带MBP TCR的细胞具有特异性,对MBP TCR转基因Rag2(-/-)小鼠进行免疫,并在体外以Cop1再次刺激。我们发现喂食Cop1后IL-4显著增加,IL-4也有类似增加。在疾病模型中,喂食Cop1可抑制MBP TCR转基因小鼠、(PL/J×SJL)F(1)小鼠以及NOD小鼠中髓鞘少突胶质细胞糖蛋白诱导的EAE。口服Cop1对胶原诱导的关节炎无作用。这些结果表明,Cop1口服时以抗原特异性方式发挥作用,可能通过减少促炎细胞因子(IFN-γ)和增加抗炎细胞因子(IL-4、IL-10和TGF-β),作为针对携带MBP特异性TCR细胞的一种改变肽配体发挥作用。